Analysts Offer Insights on Healthcare Companies: Aerie Pharma (NASDAQ: AERI), Portola Pharma (NASDAQ: PTLA) and Versartis (NASDAQ: VSAR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aerie Pharma (NASDAQ: AERI), Portola Pharma (NASDAQ: PTLA) and Versartis (NASDAQ: VSAR).

Aerie Pharma (NASDAQ: AERI)

In a report released today, Adnan Butt from RBC Capital reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI), with a price target of $55. The company’s shares opened today at $31.01.

According to TipRanks.com, Butt is ranked 0 out of 5 stars with an average return of -5.1% and a 42.2% success rate. Butt covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Intra-Cellular Therapies, and Synthetic Biologics Inc.

Currently, the analyst consensus on Aerie Pharma is Strong Buy and the average price target is $44, representing a 41.9% upside.

In a report issued on September 7, Stifel Nicolaus also maintained a Buy rating on the stock with a $40 price target.
Portola Pharma (NASDAQ: PTLA)

In a report released today, Matthew Harrison from Morgan Stanley reiterated a Buy rating on Portola Pharma (NASDAQ: PTLA), with a price target of $28. The company’s shares opened today at $23.29, close to its 52-week low of $18.20.

Harrison observed, “We hosted a small group lunch with CEO Bill Lis, CFO Mardi Dier, and R&D head John Curnutte.”

According to TipRanks.com, Harrison is a 4-star analyst with an average return of 4.7% and a 60.4% success rate. Harrison covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Syndax Pharmaceuticals Inc, and Achillion Pharmaceuticals.

Portola Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $32.67.

Versartis (NASDAQ: VSAR)

Morgan Stanley analyst Andrew Berens reiterated a Hold rating on Versartis (NASDAQ: VSAR) today and set a price target of $17. The company’s shares opened today at $12.98.

According to TipRanks.com, Berens is a 4-star analyst with an average return of 7.2% and a 64.2% success rate. Berens covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Amag Pharmaceuticals, and Akebia Therapeutics.

Versartis has an analyst consensus of Moderate Buy, with a price target consensus of $13.